Tag: Hybrid Pharma-DTx Models

For a few years, digital therapeutics were treated as inevitable. Prescription apps would scale like software, improve outcomes like medicines, and disrupt chronic care economics along the way. Venture capital flowed, regulatory clearances multiplied, and early reimbursement wins were celebrated as proof that the model... Continue reading